+ ERX-41 | etiraRx ERX-41 | etiraRx ERX-41


Outsmarting Tumor Heterogeneity

There are more than 250,000 patients suffering from metastatic breast cancer today. Unfortunately, 43,700 of them will not survive till the end of the year. The primary reason is tumor heterogeneity, which means that different cancer cells have distinct morphological and phenotypic profiles and differential sensitivity to therapies.

The world needed a breakthrough for these patients. A breakthrough that our passionate, driven, and unrelenting team was able to achieve by following the science. More than a decade of work culminated in a paper published in Nature Cancer in July 2022, where we identified a new approach to overcoming tumor heterogeneity- by targeting a vulnerability common to most cancer cells and a breakthrough agent to target this vulnerability – ERX-41.

ERX-41 represents

  • Our breakthrough agent that targets solid tumors by inducing endoplasmic reticulum stress.
  • The first therapy to induce sustained and uncompensated endoplasmic reticulum stress causing cell death.
  • The first targeted agent against LIPA’s role in the endoplasmic reticulum. (ER+, ER-, TNBC).
  • The only oral agent with cytotoxic activity against most forms of breast cancer (ER+, ER-, TNBC).
  • A new hope for patients with metastatic therapy-resistant breast cancers.


*These statements are based on preclinical research and have not been evaluated in clinical trials nor by the FDA or any government health agency.

Read more about ERX-41 in the recent publication in Nature Cancer from the lab of etiraRx founders, Dr. Ganesh Raj, Dr. Ratna Vadlamudi and Dr. Jung-Mo Ahn: Targeting LIPA independent of its lipase activity is a therapeutic strategy in solid tumors via induction of endoplasmic reticulum stress.

ERX-41 performance in vitro



Green fluorescents released from cells as they die, and indicates cell death